about
Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literatureMortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based CohortAutoimmune neutropenia and thrombocytopenia associated with development of antibodies to human immunodeficiency virus.Adenosine deaminase activity in rheumatoid pleural effusion.Epidemiology of infections by HIV, Syphilis, Gonorrhea and Lymphogranuloma Venereum in Barcelona City: a population-based incidence study.Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patientsTropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.[Visceral leishmaniasis in patients with HIV infection]Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.[Clinical characteristics and diagnostic difficulties in 35 cases of tuberculous meningitis][Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)]Hodgkin's disease in patients with antibodies to human immunodeficiency virus. A study of 22 patients.[Hepatic and serum bile acid changes in pneumonia]Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients.Influence of human immunodeficiency virus 1 infection and degree of immunosuppression in the clinical characteristics and outcome of infective endocarditis in intravenous drug users.Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.[Utility of determining fasting and postprandial cholylglycine and sulfolithocholylglycine in the diagnosis of hepatic cirrhosis]Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjectsEfficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patientsPharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosisAtazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimenSerological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up studyA Case of Multiorgan Failure Following Interruption of Antiretroviral Treatment[Pleural cryptococcosis in patients with human immunodeficiency virus infection][Ulcer in the urethral meatus and HIV infection][Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection]Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodesDiagnostic value of ascites gamma interferon levels in tuberculous peritonitis. Comparison with adenosine deaminase activityLymphocyte Proliferation and Gamma-Interferon Production after “in Vitro” Stimulation with PPD[Gamma interferon and adenosine deaminase in pleuritis]Adenosine deaminase in body fluids: A useful diagnostic tool in tuberculosis[Lymphocyte response to mitogens and antigens in pleurisy]
P50
Q28082149-74F03B80-1873-4242-9E52-7DD79794EFF3Q28551895-56C8E51E-1C93-4089-AA76-E8EFD704C9BEQ33431572-A46AC5ED-B5D6-4196-9494-9AB0FAC7B44AQ33560862-85A65182-C8F7-4391-81B8-D61BD1EC6E47Q35799788-79FF40AC-28BB-4441-A647-A664A1B8AC57Q36158135-773C41D2-843A-445A-B2A7-36EE18D5C95EQ37119579-FB2E22E3-2FDA-4855-B180-BC7BB3B8B1B8Q40188071-5E0BD298-12DF-45E8-8D2A-BBA65199725CQ40689401-939CF569-2FED-461F-917C-D7D2C7937110Q40836654-38A888FA-2144-42C6-935C-5DA20C14EFC4Q41733883-DC501C82-1398-4B48-A6B4-4802ED248D51Q42200753-6C718AFE-1370-466C-897F-09A9CC48174AQ42936157-30C1A3AC-E175-41AC-95AB-570B1FEF6698Q42986040-297CEF47-2033-445E-B713-6CD424C383ECQ43047302-771D1C31-7A66-4410-991E-1E866D29A684Q43298626-4CC57EB9-1413-464F-B3B9-E2A48549F3FBQ43949280-01C62798-52CD-40A4-B95B-A418E6F5BC34Q43950093-774641A1-4499-446F-B175-B08616CDAC2DQ44930055-073D05DC-B520-4C49-9622-8641529631E6Q44954149-A049D083-71C7-4716-A023-BF7BFCCCC540Q45745936-B4E70BF5-2E56-4EA6-B3FE-5A4F9836A3EFQ45753406-BA7F0311-2D50-4E02-A2B6-50BB6B4F61CFQ46694431-C3C66469-37BF-4734-AA47-D631DF427BEFQ51643154-9E8C607A-5C9D-4BE6-9D2A-91E57B9184ACQ51789830-D0E0D47C-B734-4630-AFDE-B08CDBFBF380Q56794468-0700B8A9-CC7E-40A4-9E74-22DEE03CA367Q58204749-272260FA-DE36-42E0-BCE1-035DDAD226C7Q58204755-098C5E06-EBCA-4B8D-AB7C-B70AB30CFBF9Q58204770-A074DE96-8ADE-48DE-9ACC-2E5C1E268211Q58204779-82267CD1-F4E3-49C7-B183-89752E7E2FF7Q58204802-BC64A404-E6B2-440C-9678-6E5A3F3FE604Q58204845-4C4DAA73-714B-4ECC-B808-F7DE0850FA95Q58204851-7AF991E5-E9FB-45C9-A825-6B5E0DCA4648Q58204864-D86A7C69-931C-4312-85C1-C8FC2225C89AQ58204876-20544E34-2F64-4060-8DBA-AE425C26D969Q58204896-A7D42D65-F60D-4F0E-B292-E58591C251A0Q58204903-28E6613B-27AA-4119-9EB7-FCF02EFB6D16Q58204908-5CE40AFA-30D6-4B34-922E-CF89701D4762Q58204918-4136CD5F-C672-4102-9732-5BDF8A9A1799Q58204926-10D4107E-7DD2-4D42-9112-836465C8F8C2
P50
description
forsker
@nb
researcher ORCID ID = 0000-0003-3699-0790
@en
wetenschapper
@nl
name
I. Ocana
@ast
I. Ocana
@nl
Inma Ocana
@en
Inma Ocana
@nb
type
label
I. Ocana
@ast
I. Ocana
@nl
Inma Ocana
@en
Inma Ocana
@nb
altLabel
I. Ocana
@en
prefLabel
I. Ocana
@ast
I. Ocana
@nl
Inma Ocana
@en
Inma Ocana
@nb
P106
P31
P496
0000-0003-3699-0790